25,729 articles
Atezolizumab/bevacizumab regimen
The atezolizumab/bevacizumab regimen is a cancer drug combination pairing a PD-L1 checkpoint inhibitor with an anti-VEGF antibody, approved in 2020 as standard first-line therapy for unresectable liver cancer after the IMbrave150 trial.
ATG-106
ATG-106 is Antengene's preclinical "2+1" sterically masked CDH6 x CD3 bispecific T-cell engager for ovarian and kidney cancer, licensed in June 2026 to MPM BioImpact-established K2 Therapeutics for about $20 million upfront plus up to $960.5 million in milestones, ex-Greater China.
ATG-201
ATG-201 is Antengene's investigational "2+1" CD19/CD3 bispecific T-cell engager for B cell-related autoimmune diseases, using steric hindrance masking to lower CRS risk; UCB licensed it worldwide in March 2026 for up to about USD 1.2 billion.
Athabaskan brainstem dysgenesis syndrome
Athabaskan brainstem dysgenesis syndrome (ABDS, formerly Navajo brainstem syndrome) is a rare autosomal recessive HOXA1 disorder of Navajo and Apache children causing horizontal gaze palsy, deafness, central hypoventilation, and developmental delay.
Atherectomy
Atherectomy: catheter-based removal of arterial plaque by cutting, shaving, sanding, or vaporizing; four device types (directional, rotational, orbital, laser) used in peripheral and coronary artery disease.
Atheroma
Atheroma (atherosclerotic plaque): lipid- and foam-cell-rich deposit with a fibrous cap in medium and large artery walls; thin-cap fibroatheroma (<65 µm cap) ruptures, causing thrombosis, heart attack, and stroke.
Atherosclerosis
Atherosclerosis: chronic inflammatory arterial disease caused by retention of apoB lipoproteins (LDL, remnants, Lp(a)) in the intima, forming plaques that rupture; statins cut events 22% per mmol/L LDL-C.
Atherosclerosis of aorta
Atherosclerosis of aorta (ICD-11 BD40.1; aortic atheroma, aortic sclerosis): lipid-driven plaque in the aortic intima; severe ≥4 mm arch atheromas raise stroke odds about ninefold; managed with risk-factor control and statins.
Atherosclerosis of renal artery
Atherosclerosis of the renal artery (atherosclerotic renal artery stenosis, ARAS): plaque narrowing the renal arteries, causing about 90% of renal artery stenosis and secondary hypertension; treated mainly with medical therapy, revascularization reserved for select high-risk patients.
Atherosclerotic cardiovascular disease risk score
An atherosclerotic cardiovascular disease (ASCVD) risk score is a clinical tool estimating 10-year and lifetime risk of heart attack or stroke, used chiefly to guide statin therapy.
Athetosis
Athetosis: slow, sinuous, writhing involuntary movements of the distal limbs, first described by Hammond in 1871, caused by basal ganglia injury, common in dyskinetic cerebral palsy, now often classified within the dystonia spectrum.
Athlete's electrocardiogram and preparticipation screening
An athlete's electrocardiogram (ECG) is a 12-lead heart recording interpreted against standards built for trained people, and preparticipation screening aims to identify cardiac conditions that raise sudden cardiac death risk before competition.
Athlete's foot
Dermatophytosis of foot, also called tinea pedis or athlete's foot (ICD-11 1F28.2), is a superficial dermatophyte fungal infection of the feet, mainly toe webs and soles, caused chiefly by Trichophyton rubrum and T. interdigitale, treated with topical antifungals.
Athlete's heart
Athlete's heart is the benign set of changes, including chamber enlargement and a slow resting heart rate, that regular athletic training produces; it can mimic hypertrophic cardiomyopathy.
Athletic heart syndrome
Athletic heart syndrome, or exercise-induced cardiac remodeling, is the physiological heart enlargement and electrical change from repetitive strenuous training, first described by Henschen in 1899, and distinguished from cardiomyopathy by reversibility with detraining.
Athyreosis
Athyreosis (thyroid agenesis) is the complete absence of thyroid tissue, a rare form of thyroid dysgenesis causing permanent congenital hypothyroidism from birth; ICD-10 E03.1, OMIM 218700, treated with lifelong levothyroxine.
Aticaprant
Aticaprant is an oral, short-acting kappa opioid receptor antagonist that Johnson & Johnson developed as an add-on therapy for depression, discontinued in March 2025 after its Phase 3 trials failed.
Atidarsagene autotemcel
Atidarsagene autotemcel (Lenmeldy, Libmeldy) is an autologous hematopoietic stem cell gene therapy encoding ARSA, approved by the EMA in 2020 and FDA in 2024 for pre-symptomatic and early juvenile metachromatic leukodystrophy in children.
Atilotrelvir/ritonavir
Atilotrelvir/ritonavir (泰中定, GST-HG171) is a Chinese oral 3CL protease inhibitor combination for mild-to-moderate COVID-19, conditionally NMPA-approved November 2023; 150/100 mg twice daily for 5 days.
Atkin-Flaitz syndrome
Atkin-Flaitz syndrome (X-linked intellectual disability, Atkin type; OMIM 300431) is a very rare X-linked dominant disorder with intellectual disability, macrocephaly, short stature, distinctive facies, seizures, and macroorchidism, described in one family in 1985.
Atkins diet
Atkins diet: low-carbohydrate weight-loss plan by cardiologist Robert Atkins, first published 1972; four phases starting at 20 g carbs/day, ketosis-based mechanism, Atkins 20/40/100 versions, short-term trial efficacy that fades by 12 months.
Atlanto-axial dislocation
Atlanto-axial dislocation (AAD), also called atlantoaxial subluxation, is loss of alignment between the C1 atlas and C2 axis. Caused by trauma, rheumatoid arthritis, or congenital disorders; diagnosed by ADI over 5 mm; treated with C1-C2 fusion.
Atlas (anatomy)
Atlas (C1), first cervical vertebra: a ring-shaped bone with no body or spinous process that supports the skull, articulates with the occipital condyles and axis, and provides about half of head rotation.
Atogepant
Atogepant (Qulipta, Aquipta) is an oral small-molecule CGRP receptor antagonist (gepant) for preventing migraine in adults; FDA-approved 2021, EU 2023, reducing monthly migraine days by about 1.2 to 2.4 versus placebo.
Atoltivimab
Atoltivimab (REGN3470) is a fully human monoclonal antibody that Regeneron Pharmaceuticals combines with two other antibodies in Inmazeb, an Ebola treatment approved by the FDA in 2020.
Atomoxetine
Atomoxetine (Strattera), a selective norepinephrine reuptake inhibitor, is the first non-stimulant FDA-approved ADHD medication (2002, Eli Lilly), used after stimulant failure or intolerance, metabolized by CYP2D6, with a pediatric suicidal-ideation boxed warning; brand discontinued in favor of generics.
Atonia
Atonia is the complete loss of muscle tone, an ICD-11 symptom code (MB45.2) and a normal feature of REM sleep. Its failure causes REM sleep behavior disorder; inappropriate activation causes cataplexy in narcolepsy.
Atopic dermatitis
Atopic dermatitis (eczema) is a chronic, itchy inflammatory skin disease affecting up to 25% of children, driven by skin barrier defects, Th2 inflammation, and pruritus; treated with topicals, biologics like dupilumab, and JAK inhibitors.
Atopic dermatitis in infants and children
Atopic dermatitis in infants and children, also called atopic eczema, is a chronic itchy inflammatory skin disease that usually begins before age 5 and often improves with age.
Atopic keratoconjunctivitis
Atopic keratoconjunctivitis, first described by Hogan in 1953, is a chronic bilateral inflammation of the conjunctiva and cornea in people with atopic dermatitis, and can threaten vision.